Grace Therapeutics Secures $4M in Additional Funding
ByAinvest
Thursday, Oct 23, 2025 8:07 am ET1min read
GRCE--
Grace Therapeutics has secured $4.0 million in additional funding through the exercise of common warrants issued in a 2023 private placement. The company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining common warrants have expired as the FDA has accepted the New Drug Application for GTx-104 for review.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet